Call for global approach to developing biosimilars

The European Generics Industry is calling for a world wide standard to develop biosimilars. Leaders believe standards need to be set for the industry world wide in order to create a consistent, scientific global approach in order to fully reach the potential that biosimilars can have world wide.

Greg Perry, director general of the European Generic Medicines Association (EGA), stated, "If healthcare systems are to continue to function long-term, we must address the importance of biosimilar monoclonal antibodies (MAbs) next. Science for MAbs is already here today and our industry is expecting a workable guideline."

Do you think a global, united front on biosimilars will aid the development of them? What could be the benefits of the scientists of the world having the same standards for developing biosimilars?

Share this article with your social network, just click below to share now!

Share |